Pharma

Unichem Laboratories receives ANDA approval for Apremilast Tablets

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .

  • By ICN Group | February 20, 2021

Unichem Laboratories Limited has received ANDA approval for its Apremilast Tablets, 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Amgen's Otezla (apremilast) Tablets, 10 mg, 20 mg, and 30 mg.

 

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

'Participate in ICN Compendium on Chemical Industry Outlook 2021' Click here to know more

Startup

Chemical

Petrochemical

Digitization

Gas

India should focus on pharma intermediates self-sufficiency
Dr. K. Nagaiah CSIR-IICT, Hyderabad,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge
India should focus on pharma intermediates self-sufficiency